Delayed clinical trial data delivery is a growing problem for pharmaceutical companies and one that can have catastrophic consequences for the development of their promising pipeline candid
In the US, fewer than three per cent of eligible patients participate in clinical trials – a figure that drops drastically when applied to ethnic minorities living in underserved communities.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
